MEK Inhibitor SHR 7390 clinical trials
Also written SHR7390.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses MEK Inhibitor SHR 7390 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SHR7390
- 4
Studies by the year they started
4 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 2
Jiangsu HengRui Medicine Co., Ltd. (2) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · Fudan University (1)
Often tested with
Tested in the same studies.
Camrelizumab (2) · Fluzoparib (2) · Famitinib (1) · Pyrotinib (1) · Everolimus (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Zeprumetostat (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses MEK Inhibitor SHR 7390 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate CancerCompletedPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT04676607Written as SHR7390
- The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid TumorsTerminatedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT03182673Written as SHR7390
- Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownPhase 2Fudan UniversityNCT04355858Written as SHR7390
- Phase I Study of SHR7390 in Patients With Advanced Solid TumorsStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT02968485Written as SHR7390